Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Latest News
    • Clinical trial finds...

    Clinical trial finds method to reverse brain necrosis due to radiation

    Written by Hina Zahid Published On 2019-05-15T19:28:24+05:30  |  Updated On 15 May 2019 7:28 PM IST
    Clinical trial finds method to reverse brain necrosis due to radiation

    New Clinical trial finds a method to reverse brain necrosis due to radiation.


    A new procedure pioneered by Norton Healthcare physician-scientists directly targets brain tissue affected by radiation necrosis.The scientists have conducted a clinical trial and found that a small dose of the cancer drug Avastin can help revert brain necrosis.


    Radiation therapy is an effective way to treat certain brain arteriovenous malformations, AVMs. In up to 5 per cent of cases, however, it can cause damage to the surrounding brain. This can result in radiation necrosis when the nearby brain tissue becomes injured and dies.


    The Clinical trial, led by Shervin Dashti, M.D., Ph.D., an endovascular neurosurgeon with Norton Neuroscience Institute, is the first in the world to deliver a single small dose of the cancer drug Avastin directly to the area of the brain affected by the necrosis. Tom Yao, M.D., an endovascular neurosurgeon with Norton Neuroscience Institute, and Justin Fraser, M.D., a neurosurgeon with UK HealthCare, also are treating patients in the study.


    Avastin previously has been used effectively to treat radiation necrosis. The medication is given through an IV, meaning the drug has to circulate through the body before only a small percentage reaches the brain in the Clinical trial. When the drug does reach the brain, it has a hard time penetrating because of a natural defense mechanism called the blood-brain barrier. Making matters worse, exposing the body to Avastin can result in brain bleeds, clots, and uncontrolled high blood pressure.


    What makes the new treatment innovative is it delivers a very small dose of Avastin directly into the artery going to the affected part of the brain. The smaller dose should significantly decrease the serious and life-threatening side effects of the drug. Also, with the targeted delivery, a lot more of the drug will get to where it needs to go.


    The condition can be disabling, causing severe headaches, nausea and vomiting, seizures, cognitive issues and even death.


    "I started losing my sight and then passed out," Alyssa Coffey recalled about experiencing her first seizure.


    Coffey was in the midst of training for an upcoming bodybuilding competition. A scan revealed the then 23-year-old New Jersey resident had an arteriovenous malformation (AVM), a tangle of abnormal blood vessels connecting arteries and veins in the brain.


    To treat the AVM, doctors in her home state used radiation therapy. The radiation therapy treated the AVM, but Coffey experienced the severe side effect of radiation necrosis.


    Doctors use a variety of medications, such as steroids, to manage the symptoms. None of the medications works very well, and all have serious side effects. There is no approved cure.


    "It was miserable," Coffey said. "The necrosis impacted my ability to work. Going to the gym was out of the question."


    Doctors in New Jersey suggested exploratory brain surgery, but Coffey felt it was too risky.


    Last year, while on an AVM support group website, Coffey learned about a study at Norton Neuroscience Institute in Louisville, Kentucky, and the University of Kentucky that sought to reverse radiation necrosis.


    What makes the new treatment innovative is it delivers a very small dose of Avastin directly into the artery going to the affected part of the brain. The smaller dose should significantly decrease the serious and life-threatening side effects of the drug. Also, with the targeted delivery, a lot more of the drug will get to where it needs to go.


    To make the drug more effective, Dr. Dashti uses a special technique to open the blood-brain barrier by infusing a mannitol sugar solution into the carotid artery. When this is done right before injecting the Avastin, a much larger amount of the drug can reach the affected brain tissue while minimizing drug exposure to the rest of the body.


    "I felt this was my best option," Coffey said. "And I was confident it was going to work."


    MEDICATION YIELDS POSITIVE RESULTS


    Coffey flew to Louisville to receive her single-dose treatment. In a 45-minute procedure, Dr. Dashti injected the Avastin into her brain through an artery in her leg and immediately began studying the effects.


    It didn't take long for Coffey to see a difference.


    "The headaches went away in a matter of weeks," she said. "I was able to go off my other medications and get back into the gym."


    Her scans also told a positive story.


    "The images showed great improvement in the area impacted by the necrosis," Dr. Dashti said. "We were very encouraged with what we were seeing."


    STILL GOING STRONG — AND GETTING STRONGER


    It's been a year since Coffey received her injection. She recently returned to Louisville for a follow-up exam. The headaches are now a distant memory, and her brain scans are showing further improvement. She said she's feeling great and is even back to training for another bodybuilding competition.


    "Participating in the trial was the best thing I could have done," she said. "I've received tremendous care throughout. I feel like I have my life back."


    Dr. Dashti said other patients in the trial also are seeing similar results.


    "To this point, everyone who has received the Avastin has seen improvement in their condition," he said. "It's very exciting."


    While the findings are encouraging, Dr. Dashti points out that the treatment is still a long way from becoming common practice.


    "We studied a very small group of people, and we still have to determine if the benefits are long-term," he said. "Hopefully, we'll look to get funding for a larger, multicenter study in the future."


    For now, he's excited about the possibilities.


    "I think we have a chance to change the way we treat radiation necrosis and help more people," Dr. Dashti said.


    You can be a part of life-changing work at Norton Neuroscience Institute. Make a donation to the Norton Healthcare Foundation to help.

    blood pressurebrain bleedsbrain necrosisbrain tissueclinical trialsCoffeygymhigh blood pressureJustin FraserNorton Healthcare FoundationNorton Neuroscience Instituteradiation necrosisShervin DashtiTom Yao

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Hina Zahid
    Hina Zahid
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok